Humabs launches with preclinical infection MAbs to partner
This article was originally published in Scrip
Executive Summary
Humabs BioMed has been launched as an independent company based in Switzerland, some seven years after its formation as an incubator for two platform antibody technologies. The firm, which received early angel investment from Dr Bill Rutter, its chairman and former chairman of Chiron, was originally established as a Delaware-incorporated company, but is now fully transferred to Switzerland, where it conducts its work in close co-operation with the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland.